PD1/PD-L1 pathway in psoriasis and psoriatic arthritis:
a review

Michał Adamczyk; Dorota Krasowska

doi:10.5114/ada.2021.112274

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

6/2021
vol. 38

Send email

Copy url:

abstract:

Review paper

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review

Michał Adamczyk

¹

,

Dorota Krasowska

¹

Department of Dermatology, Venerology and Paediatric Dermatology, Medical University of Lublin, Lublin, Poland

Adv Dermatol Allergol 2021; XXXVIII (6): 925–930

DOI: https://doi.org/10.5114/ada.2021.112274

Online publish date: 2022/01/07

View full text Get citation

Programmed-death 1 (PD-1) is a co-receptor that inhibits the inflammatory response, and thus helps in maintenance of peripheral immunotolerance. Impairment in the PD-1/PD-L1 pathway is believed to play an important role in many immune-mediated diseases, including systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and autoimmune hepatitis, and, as emphasized recently, in psoriasis and psoriatic arthritis. Biologic drugs targeting immune checkpoint regulators may be associated with new-onset psoriasis or exacerbations of pre-existing dermatosis. In this review we discuss the role of PD-1/PD-L1 pathway in psoriasis basing on data published to date.

keywords:

PD1/PD-L1 pathway in psoriasis and psoriatic arthritis: a review

Michał Adamczyk 1 , Dorota Krasowska 1

psoriasis, psoriatic arthritis, PD-1/PD-L1, immune checkpoint

Michał Adamczyk

¹

,

Dorota Krasowska

¹